Tbh, after reading the announcement again, it is very clear that RAP ought to consider strongly a clinical research PhD (ie a medical practitioner, preferably an experienced paediatrician or respiratory physician, with a clinical research PhD) with an appropriate skillset to lead their involvement in a second trial and do a dummy run perhaps, or more than one, to iron out potentially catastrophic variables.
Apologies if this was already done.
- Forums
- ASX - By Stock
- Ann: Preliminary Top-line Results from SMARTCOUGH-C Study
Tbh, after reading the announcement again, it is very clear that...
-
-
- There are more pages in this discussion • 229 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)